BRIEF-Sangamo Therapeutics & Astellas Enter Capsid License Agreement

Reuters12-19

Dec 19 (Reuters) - Sangamo Therapeutics Inc & Astellas Pharma Inc :

* SANGAMO THERAPEUTICS AND ASTELLAS ANNOUNCE CAPSID LICENSE AGREEMENT TO DELIVER GENOMIC MEDICINES FOR NEUROLOGICAL DISEASES

* SANGAMO THERAPEUTICS INC - ELIGIBLE FOR UP TO $1.3 BILLION IN MILESTONE PAYMENTS

* SANGAMO THERAPEUTICS INC - TO RECEIVE $20 MILLION UPFRONT LICENSE FEE

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492111727?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 15:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492111727","market":"us","top_or_hot":-1,"title":"BRIEF-Sangamo Therapeutics & Astellas Enter Capsid License Agreement","media":"Reuters","content":"<html><body><p>Dec 19 (Reuters) - <a href=\"https://laohu8.com/S/SGMO\">Sangamo Therapeutics Inc</a>    &amp; Astellas Pharma Inc   :</p><p>   * SANGAMO THERAPEUTICS AND ASTELLAS ANNOUNCE CAPSID LICENSE AGREEMENT TO DELIVER GENOMIC MEDICINES FOR NEUROLOGICAL DISEASES</p><p>   * SANGAMO THERAPEUTICS INC - ELIGIBLE FOR UP TO $1.3 BILLION IN MILESTONE PAYMENTS</p><p>   * SANGAMO THERAPEUTICS INC - TO RECEIVE $20 MILLION UPFRONT LICENSE FEE</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sangamo Therapeutics & Astellas Enter Capsid License Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sangamo Therapeutics & Astellas Enter Capsid License Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 15:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 19 (Reuters) - Sangamo Therapeutics Inc    & Astellas Pharma Inc   :   * SANGAMO THERAPEUTICS AND ASTELLAS ANNOUNCE CAPSID LICENSE AGREEMENT TO DELIVER GENOMIC MEDICINES FOR NEUROLOGICAL DISEASES ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGMO","symbol_name":"Sangamo Therapeutics Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2492111727","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492111727","pubTimestamp":1734593731,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 19  - Sangamo Therapeutics Inc    & Astellas Pharma Inc   :   * SANGAMO THERAPEUTICS AND ASTELLAS ANNOUNCE CAPSID LICENSE AGREEMENT TO DELIVER GENOMIC MEDICINES FOR NEUROLOGICAL DISEASES   * SANGAMO THERAPEUTICS INC - ELIGIBLE FOR UP TO $1.3 BILLION IN MILESTONE PAYMENTS   * SANGAMO THERAPEUTICS INC - TO RECEIVE $20 MILLION UPFRONT LICENSE FEESource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SGMO":"Sangamo Therapeutics Inc","BK4139":"生物科技","LENZ":"Therapeutics","BK4556":"基因编辑"},"translate_title":"简介-Sangamo Therapeutics与Astellas签订衣壳许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"SGMO":0.9},"content_text":"Dec 19 (Reuters) - Sangamo Therapeutics Inc    & Astellas Pharma Inc   :   * SANGAMO THERAPEUTICS AND ASTELLAS ANNOUNCE CAPSID LICENSE AGREEMENT TO DELIVER GENOMIC MEDICINES FOR NEUROLOGICAL DISEASES   * SANGAMO THERAPEUTICS INC - ELIGIBLE FOR UP TO $1.3 BILLION IN MILESTONE PAYMENTS   * SANGAMO THERAPEUTICS INC - TO RECEIVE $20 MILLION UPFRONT LICENSE FEESource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492111727"}